Jonathan Menachem is a Cardiology physician affiliated with Vanderbilt University. OpenAlex indexes 176 publications with 2,027 citations (h-index 20); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Vanderbilt Medical Center Suite 5209
Nashville, TN 37232
Telephone
615-343-3735Provider last certified this registry record 29 Aug 2023.
Clinical trials
- REHAB Fontan Failure: A Trial of Cardiac Rehabilitation
Sponsor: Stanford University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20254 payments
- Abbott LaboratoriesProgram year202441 payments$10,916openpaymentsdata.cms.gov ↗
- CVRx, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
57.1%Angiotensin receptor-neprilysin inhibitor (ARNI)22.3%Entresto100%Part D<11 patientsBeta blocker14.3%Carvedilol100%Part D<11 patients+ 2 more classes in this area
Blood & clotting
28.6%Factor Xa inhibitor15.2%Eliquis100%Part D<11 patientsVitamin K antagonist13.4%Warfarin Sodium100%Part D<11 patientsAnti-infectives
14.3%Short-acting sulfonamides14.3%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 2025 ACC/AHA/HRS/ISACHD/SCAI Guideline for the Management of Adults With Congenital Heart Disease
Journal of the American College of Cardiology
2025 - Two hundred cases of cardiac donation after circulatory death utilizing normothermic regional perfusion: The 4-year Vanderbilt experience
The Journal of Heart and Lung Transplantation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
William Schaffner, MD
Vanderbilt University
Keith Obstein, MD, MPH
Vanderbilt University
Andrew Jallouk, MD, PhD
Vanderbilt University
Salim Yusuf
Vanderbilt University
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”